GWPH News and Press, GW Pharmaceuticals Plc From 08/06/19

GW Pharmaceuticals plc (GWPH) Q2 2019 Earnings Conference Call August 6, 2019 4:30 PM ET Company Participants Stephen Schultz – Vice President-Investor Relations Justin Gover – Chief Executive Officer Darren Cline – U.S. Chief Commercial Officer Chris Tovey...

GW Pharmaceuticals (NASDAQ: GWPH ) Q2 results : More news on: GW Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

GW Pharmaceuticals (NASDAQ: GWPH ): Q2 GAAP EPS of $0.21 beats by $0.23 . Revenue of $72.04M (+2083.0% Y/Y) beats by $26.47M . Shares +7% . Press Release More news on: GW Pharmaceuticals plc, Earnings news and commentary, Stocks on the move, Healthcare stocks news,

- Epidiolex U.S. Q2 net sales of $68.4 million - - Positive CHMP opinion clears way for an expected European approval in October - - Conference call today at 4:30 p.m. EST - CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the ...

The Formula One Scuderia Ferrari sponsored by AMD (photo via Jisakutech ). A Hedged Portfolio Around A AMD Position Last August, I wrote about the performance of a bulletproof, or hedged, portfolio built around a position in AT&T ( T ) in 2017 and presented a new one, which comp...

During the past trading week (July 22 to 26), a maligned Canadian cannabis firm removed executives from leadership positions at the company. A plan from Quebec to ban most edible cannabis products made headlines, and the launch of a new cannabis exchange-traded fund (ETF) also caught atten...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of GW Pharmaceuticals plc's (NASDAQ: GWPH ) EPIDYOLEX (cannabidiol oral solution) for the adjunctive treatment of seizures associated with Lennox-Gastaut or Dravet syndromes. More new...

If approved cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsy GW’s cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the ...

GW Pharmaceuticals (NASDAQ: GWPH ) is expected to announce its results on August 7. Sales figures for its epidiolex drug for childhood epilepsies will be a key indicator. Off-label indications may start to give an unexpected boost to the numbers. Sales of sativex should also be closely monitor...

LONDON, July 23, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will a...